Cargando…

Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients

OBJECTIVE: Our previous study showed that insulin resistance (IR) was related to endometrial hyperplasia as well as endometrial cancer. But the exact impact of IR on fertility-sparing treatment in endometrial hyperplasic disease is unclear. This study investigated how IR affects fertility-sparing tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Bingyi, Xie, Liying, Zhang, Hongwei, Zhu, Qin, Du, Yan, Luo, Xuezhen, Chen, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920219/ https://www.ncbi.nlm.nih.gov/pubmed/29533020 http://dx.doi.org/10.3802/jgo.2018.29.e35

Ejemplares similares

Effects of Weight Status and Related Metabolic Disorders on Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrial Cancer: A Retrospective Study
por: Liu, Sijia, et al.
Publicado: (2022)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
por: Chen, Junyu, et al.
Publicado: (2022)

Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Wu, Pengfei, et al.
Publicado: (2022)

Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome
por: Wang, Lulu, et al.
Publicado: (2021)

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy
por: Chen, Junyu, et al.
Publicado: (2021)

Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions
por: Contreras, Nayanar-Adela, et al.
Publicado: (2022)

Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy
por: Ga, Hiromi, et al.
Publicado: (2023)

Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia
por: Zhang, Xiaobo, et al.
Publicado: (2022)

Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience
por: Shikeli, Sumaya, et al.
Publicado: (2020)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
por: Murakami, Isao, et al.
Publicado: (2023)

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia
por: Shan, Weiwei, et al.
Publicado: (2014)

Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
por: Zhang, Qing, et al.
Publicado: (2017)

Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia
por: Fan, Yuan, et al.
Publicado: (2021)

Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with Lynch Syndrome: Molecular diagnosis after immunohistochemistry of MMR proteins
por: Catena, Ursula, et al.
Publicado: (2022)

The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
por: Guan, Jun, et al.
Publicado: (2018)

Effect and Management of Excess Weight in the Context of Fertility-Sparing Treatments in Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer: Eight-Year Experience of 227 Cases
por: Shan, Ying, et al.
Publicado: (2021)

Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study
por: Wang, Yiqin, et al.
Publicado: (2021)

Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Ding, Yingqiao, et al.
Publicado: (2022)

Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review
por: Wei, Jing, et al.
Publicado: (2017)

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma
por: Jing, Chu-Yu, et al.
Publicado: (2022)

Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology
por: Ushijima, Kimio, et al.
Publicado: (2023)

Insulin Resistance and Metabolic Syndrome Increase the Risk of Relapse For Fertility Preserving Treatment in Atypical Endometrial Hyperplasia and Early Endometrial Cancer Patients
por: Li, Xingchen, et al.
Publicado: (2021)

The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer
por: Guan, Jun, et al.
Publicado: (2022)

Fertility-Sparing Treatment and Assisted Reproductive Technology in Patients with Endometrial Carcinoma and Endometrial Hyperplasia: Pregnancy Outcomes after Embryo Transfer
por: Friedlander, Hilary, et al.
Publicado: (2023)

PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia
por: Xue, Yu, et al.
Publicado: (2023)

Fertility-sparing treatment in women with endometrial cancer
por: Won, Seyeon, et al.
Publicado: (2020)

Fertility-sparing treatment for patients with endometrial carcinoma
por: Ind, T
Publicado: (2023)

Lymph node dissection in atypical endometrial hyperplasia
por: Taşkın, Salih, et al.
Publicado: (2017)

Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)
por: Mitsuhashi, Akira, et al.
Publicado: (2020)

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer
por: Holland, C M, et al.
Publicado: (2003)

PPOS Protocol Effectively Improves the IVF Outcome Without Increasing the Recurrence Rate in Early Endometrioid Endometrial Cancer and Atypical Endometrial Hyperplasia Patients After Fertility Preserving Treatment
por: Chen, Jiazhou, et al.
Publicado: (2021)

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022)

Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis
por: Li, Miaomiao, et al.
Publicado: (2019)

Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia
por: Inoue, Osamu, et al.
Publicado: (2016)

Analysis of Factors Associated With Recurrence of Early-Stage Endometrial Carcinoma and Atypical Endometrial Hyperplasia in Infertile Women After In Vitro Fertilization Treatment
por: Guo, Yaxing, et al.
Publicado: (2022)

Audit of waiting time‐to‐treatment of atypical endometrial hyperplasia
por: Anderson, Annabel, et al.
Publicado: (2022)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

Risk of atypical hyperplasia and endometrial carcinoma after initial diagnosis of non-atypical endometrial hyperplasia: A long-term follow-up study
por: Prip, Clara M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rsul9uhrc9e5jbce6vh6jmt61c